← Human Trials & Peer-Reviewed Studies
Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study
Plain-language guide to PMID 11926556 (2002): double-blind randomized controlled trial study of Somatostatin and Lanreotide, pancreatitis (after the acute phase).
Key Facts
- PMID
- 11926556
- Journal
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Falconi M et al. (6 authors)
- DOI
- 10.1016/s1590-8658(02)80242-0
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin and Lanreotide in the context of pancreatitis (after the acute phase).
To establish the effects of the somatostatin analogue lanreotide on exocrine pancreatic secretion.
Why It Was Studied
Total parenteral nutrition and somatostatin or analogues represent a consolidated therapeutic approach for external fistulas, a frequent complication of major pancreatic surgery.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Somatostatin.
A placebo (an inactive look-alike) gave the Somatostatin group a baseline to be compared against.
Each person switched between Somatostatin and the comparison at some point, usually with a gap in between.
What Was Measured
PubMed files the paper under topics including Bicarbonates, Gastrointestinal Agents, Glucagon, Insulin, Pancreas, Pancreatic Neoplasms and Pancreaticoduodenectomy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Lanreotide in people with pancreatitis (after the acute phase).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2002 (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver), a journal based in Netherlands.
More context: the Somatostatin compound page and the Lanreotide compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.